Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Alcon to pay €375m for rights to eye disease drug

Ocriplasmin is potential first non-surgical treatment for vitreomacular adhesion

Novartis' recently-acquired ophthalmology unit Alcon has licensed non-US rights to a drug to treat a serious eye disease from ThromboGenics in a €375m deal.

Under the agreement, Alcon gains exclusive rights to ocriplasmin, in development as a treatment for symptomatic vitreomacular adhesion (VMA), outside the US.

Alcon will pay Belgium-based ThromboGenics €75m in an upfront licensing fee, with the remaining amount dependent on regulatory and commercial milestones. ThromboGenics also stands to receive royalties on sales.

Kevin Buehler, division head at Alcon, said: "Ocriplasmin is a strategic fit for Alcon and is expected to further enhance our portfolio of innovative treatments for the eye."

VMA is condition in which the vitreous membrane of the eye fuses to the retina, causing a pulling effect which impairs vision. In serious cases holes can appear in the macula region of the retina, causing central blindness.

There is currently no approved treatment for the disease, which affects more than 300,000 people in Europe alone, with sufferers having to rely on surgical intervention when symptoms progress.

Ocriplasmin could transform the management of patients with VMA as it could potentially stop the disease progressing from the early stages.

Ocriplasmin has been under review by the European Medicines Agency (EMA) since October 2011 and is also being assessed by the US Food and Drug Administration (FDA), with a decision due in the second half of this year under the agency's priority review mechanism.

Alcon and ThromboGenics will also work together on extending the indications of ocriplasmin to include diabetic macular oedema and age-related macular degeneration.

Analysts have suggested that the product could achieve $600m in peak annual sales in VMA alone. Alcon posted total revenues of $10bn last year.

19th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
How scientific storytelling can help Pharma cut through the noise
Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...